Jazz Samra’s Post

# Only put off until tomorrow what you are willing to die having left undone ## Seize the Opportunity and Leverage the Dip - Act Now! 💪🚀📈 In a recent article published by Barchart.com, it discusses the intriguing potential of a lesser-known cannabis penny stock that has seen repeated insider buying post-earnings. With insiders demonstrating confidence in the company's growth prospects, investors are left wondering if this is an opportunity worth capitalizing on. The article highlights the significance of insider buying as a strong indicator of positive future performance. Insider buying suggests that those with intimate knowledge of the company see value and believe in its potential for long-term success. By following the lead of these insiders, investors can position themselves to leverage the current dip in the stock price. Investing in cannabis has shown significant promise, and with the ongoing legalization efforts, the industry's potential for growth is substantial. As investors, we must seize opportunities when they present themselves and not let fear of missing out hold us back. Now is the time to act and take advantage of this potential investment opportunity. By investing through your Health Savings Account \(HSA\), you not only have the potential for financial growth but also contribute to your overall well-being and healthcare needs. Maximize the benefits of your HSA and invest in this promising cannabis penny stock today. Don't miss out on the chance to grow your HSA while supporting the healthcare and wellness industry. Take action now and join the movement! 🌿💰💼 #hsa #investing #healthcare #health #family #wellness

Let's be honest - no Canadian cannabis stock has ever been worth over $1,000. Granted, this must be based on restating share prices to capture the now very popular and ever-happening reverse share split, to try to raise the price over $1.00 (only to issue more shares and/or release more bad financial results, and see it drop below a buck again). Can anyone be proud of this - any of the CEO's of these companies, be they now gone (thankfully) or soon to be gone (hopefully)? To have been given 5 years and over $100 billion in investment dollars, and this is what they have built. A money-losing, share price plummeting industry that generates over $5 billion in retail sales, but employs one hand of a machine shop teacher, to capture all the profitable companies. I have told you that 2024 will see more bankruptcy filings than any year to-date. I have also told you it will take another 18 to 24 months to see the industry start to turn to a professional, mature, ethical and truly strategic entity. There are still too many companies and too many badly run companies - the badly run ones will die off (committing suicide in most cases). But the pain is still to be felt for a bit longer. Look at Cannara Biotech and MTL (if they tighten their B/S's), Decibel (if they sell off their retail side) and Rubicon (if they stop doing dumb poutine sauce launches), as some of the better run companies. Nova, I need to see how they perform out from under the SNDL cost savings. Look for Entourage Health and Auxly and RWB and Biome Grow and a lot more to be gone.

Cannastocks' Downward Spiral: A Closer Look: #Cannabis is an agricultural product. It doesn’t follow the same rules of #technology, #finance, or consumer goods. The biggest players didn’t understand the fundamental truths about the business, said Jeff Beverly, an industry veteran and founding partner at Kola Venture Group. “They overbuilt and raced each other to the bottom,” he said. “They forgot about the most important thing in weed—quality. So many of the C-suite suits don’t even #toke. They also thought everyone wanted a spa-like #dispensary or the next Apple Store of #weed. Now, they all think #canna-beverages will save the industry.” The big problem? - #Banking #regulations that prevent big-money institutional investors—hedge funds, pension funds, endowments, etc.—to buy #stocks in cannabis. The Fix? Read more here: https://ow.ly/W20M50Rof3Z

Just wait and watch - I will be right, yet again - I am not wrong very often. Just wait and see what really happens in the US - these people who bought these stocks at these prices do not have a sweet clue - not a clue. Not a clue as to what it means and what it doesn't mean - what's going to happen and when. Heck, Tilray doesn't even have a US cannabis business - the one they kinda had, MedMen, just kinda went bankrupt - oopsie. And Aurora has no US cannabis business either, having shut down the Reliva CBD business last year. And Canopy Growth, well, they have so much existing debt and they lose so much money, how can they fund any sort of US growth (oh yeah, immediately issue more stock given the price run-up). But if you think they are somehow now smarter and more strategic because of the DEA moving to reschedule cannabis, you are dumber than a bag of hammers. I'd say give your heads a shake, but the rattling noise is annoying.

1. "Klein said that the company has repositioned itself to take advantage of what he estimates is a $50 billion North American cannabis market, adding that this may be a “generational opportunity” for investors." Uhm, well...OK...but, when this "$50 billion" market will actually exist, I would suggest, is 7 years away...and when it does happen, you are unlikely to be around, have a value proposition that wins or the money to fund the cost of competing (pick your poison). 2. “We've paid down a billion dollars worth of our debt over the past 12 months or so, so we're very confident in our balance sheet,” he said, noting that their next maturity isn’t until the end of 2025. Uhm, well...OK...but, you only have about $300 million in truly liquid assets on the Balance Sheet, with $200 million in current liabilities and over $300 million in operational cash burn on an annualized basis (and that's with BioSteel removed). 3. “While we've done that, we've been able to, in the Canadian market for example, grow our revenue for a third consecutive quarter, so we've done a lot to get this business positioned to perform in the markets in which we operate.” Uhm, well...OK...but, your total company net revenue from continued operations was down over $34 million in the first 6 months of the current fiscal year. More moons would need to align than seen at The World Synchronized Streaking Championships - there are not enough Acts of God that could be performed - there is no math, old, new or fuzzy - that puts Canopy in a position where they actually make a profit. 4. “That's why we're here, and by the way, that's why our investors should be here as well.” Uhm, well...OK...they are here because they are either stupid or have given up...kind of like you.

Cannabis capital markets continue to take investors on a rollercoaster ride. Capital raises and M&A fell in 2023, but with cannabis stocks rallying, new states legalizing and the potential of rescheduling on the horizon, 2024 is shaping up to be an exciting year for the industry. Join MGO (Macias Gini & O'Connell LLP) and Viridian Capital Advisors for a live webinar today, February 20 at 1:30 p.m. PST (4:30 p.m. EST) to discuss capital markets data from the 2023 year in review and what the outlook is for 2024. We will also discuss how proposed rescheduling — and the elimination of 280E — could impact capital investment and M&A activity moving forward. Register Here - https://lnkd.in/g856wKQr

WM Technology (MAPS), a leading technology provider in the cannabis industry, is currently facing challenges that have caught the attention of investors. Here's a breakdown of the situation: Recent Developments: Nasdaq Delinquency: MAPS received a notice from Nasdaq for failing to file its annual report on time. This delay, attributed to leadership changes and financial procedures, raises concerns about the company's reporting practices. Share Price Decline: The stock price has fallen below Nasdaq's minimum bid requirement, a common issue among cannabis companies. This adds pressure on MAPS to regain compliance and improve its financial performance. Industry Headwinds: Several cannabis companies have faced delisting or financial difficulties this year, highlighting the challenges in this evolving market. Investment Considerations: Risk Assessment: The recent developments increase the investment risk associated with MAPS. Investors should carefully evaluate the company's ability to address its compliance issues and improve its financial standing. Opportunity Assessment: Despite the challenges, the long-term growth prospects of the cannabis industry remain strong. MAPS, with its established Weedmaps platform, could still benefit from this growth if it successfully navigates its current difficulties. Due Diligence: Investors should conduct thorough research, including reviewing MAPS' financial statements and assessing its management team's ability to execute a turnaround strategy. Moving Forward: MAPS has until April 7, 2025, to regain compliance with Nasdaq's requirements. The company's actions in the coming months will be crucial in determining its future prospects. Investors should closely monitor its progress and assess the potential risks and rewards before making any investment decisions. Disclaimer: This is not financial advice. Please conduct your own research and consult with a financial advisor before making any investment decisions. #cannabisindustry #WMTechnology #Weedmaps #investing #stockmarket #riskmanagement #duediligence #Nasdaq #compliance

ARE YOU OPEN MINDED ENOUGH TO TALK ABOUT THIS? One thing that’s rarely talked about: cannabis and adult wellness industries are not just about growth, they’re about reform—legal, social, and technological. 🟩The cannabis market, for example, was valued at over $22 billion in 2023, and that’s just the start. States in the US continue to pass legislation supporting growth, and global markets are opening up. 🙇♂️But here’s the dilemma for angel investors—are you staying ahead of these shifts? With governments easing restrictions, forward-thinking investors have a unique chance to take a stake in industries on the brink of massive expansion. How are you approaching sectors that carry both societal change and financial upside? Let’s share insights. #Cannabis #SocialChange #AngelInvesting #ReformMarkets

Are you concerned that a drop in the broader equity markets will crush cannabis stocks? Over the past year, the correlation of the US cannabis MSOS ETF to the S&P 500 and Russell 2000 is just 0.18, or 18%. This indicates that the performance of one is having very little impact on the other. While things like GDP growth and inflation often drive equity indices, cannabis stocks (for better or worse) trade like a call option on federal reform. While this has worked against us over the past 1,274 days, it can also work the other way. Blending uncorrelated return streams is the best way to improve your risk-adjusted returns. Cannabis could act as both a return enhancer and a portfolio diversifier.

When is the best time to get into the #cannabis business? Right. F*cking. Now Those of us who are truly bullish on the #cannabisindustry see a bright future ahead Sure, we are certainly going through a challenging time now, but it won't last forever If there are brighter days ahead, and you're wanting to start or buy a cannabis company, there's no better time than now Here are a few of my thoughts on why 1. If you enter the space in a bear market, you have no choice but to run lean. Operating during a challenging time becomes your norm, and when markets improve, you reap the benefits. Many of the greatest companies in the US were started during recessionary times. 2. You couldn't build a company for what you can buy one for right now, and there will never be a better time to get creative with financing. Many operators who have been struggling for 4-5 years just want out. They want to be relieved of their stress and financial burden and will do deals on assets that are quite favorable to the buyer. 3. Sometimes a fresh set of eyes is exactly what a company needs to take off. Struggling operators get stuck in the rut of trying to survive. If you see an opportunity to tweak a business model or make operational changes that will change the course of a business, there might be an opportunity there. Should everyone go out and buy a cannabis business right now? Not at all. This is a brutal game and the stakes are incredibly high But, if you're planning to get in, or wanting to expand There's no time like the present In the words of the great Warren Buffet "Be fearful when others are greedy and be greedy when others are fearful"